戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 any fully expressed, progressive infections (kala-azar).
2 ses that includes visceral leishmaniasis, or Kala Azar.
3  prevalence and mortality reported levels of Kala-azar.
4 l in treating T cell-deficient patients with kala-azar.
5  have committed to reducing the incidence of kala-azar, a clinical manifestation of visceral leishman
6 ate, could have a key role in the control of kala-azar, and prevent its resurgence when paired with t
7 nosing patients before the onset of clinical kala-azar (before 14 days fever), and show that this cou
8 timing of use and accuracy of diagnostics in kala-azar control and elimination.
9                  Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrap
10                                         Post-kala-azar dermal leishmaniasis (PKDL) is a chronic, stig
11                                         Post-kala-azar dermal leishmaniasis (PKDL) is a skin conditio
12 official targets, previous data suggest post-kala-azar dermal leishmaniasis (PKDL) patients can act a
13                                         Post kala-azar dermal leishmaniasis (PKDL), a cutaneous seque
14                                         Post-kala-azar dermal leishmaniasis (PKDL), a dermal form of
15                                         Post kala-azar dermal leishmaniasis (PKDL), a heterogeneous d
16                                         Post Kala-azar dermal leishmaniasis (PKDL), caused by Leishma
17 ry canonical treatment is available for post-kala-azar dermal leishmaniasis (PKDL), clinical sequela
18 ral leishmaniasis (VL) and its sequela, post-kala-azar dermal leishmaniasis (PKDL), in a highly endem
19  accurate detection of individuals with post-kala-azar dermal leishmaniasis (PKDL).
20  patients with maculopapular or nodular post-kala-azar dermal leishmaniasis (PKDL).
21 isceral leishmaniasis and patients with post-kala-azar dermal leishmaniasis can transmit L donovani t
22 treatment, 11 (42%) of 26 patients with post-kala-azar dermal leishmaniasis were deemed infectious to
23 firmed active visceral leishmaniasis or post-kala-azar dermal leishmaniasis who presented to the Kala
24 obtained from healthy, healed VL (HVL), post kala-azar dermal leishmaniasis(PKDL) and VL subjects.
25  active visceral leishmaniasis, 26 with post-kala-azar dermal leishmaniasis, and 184 with asymptomati
26 patients with visceral leishmaniasis or post-kala-azar dermal leishmaniasis, before and after treatme
27 icipants with visceral leishmaniasis or post-kala-azar dermal leishmaniasis, before and after treatme
28  was clinical visceral leishmaniasis or post-kala-azar dermal leishmaniasis.
29  (2003) and five (2005) of the most affected Kala-azar districts had been classified as low-risk when
30 ment are important missing components of the kala-azar elimination program.
31 responses do not appear to develop in Indian kala-azar; instead, there is an initial mixed Th1-Th2 ce
32 is, also known on the Indian subcontinent as kala-azar, is a fatal form of leishmaniasis caused by th
33                      Visceral leishmaniasis (kala-azar, KA) is the most severe form of leishmaniasis,
34 ar dermal leishmaniasis who presented to the Kala-Azar Medical Research Center.
35 gh frequency of treatment failures in Indian kala-azar might be due to infection with antimony-resist
36                                             "Kala-azar" (or Indian Visceral Leishmaniasis) is a vecto
37 tor in the failure of metalloid treatment in kala-azar patients infected with antimony-resistant Leis
38 ve expressions for, and compute estimates of Kala-azar's reproduction numbers, an indirect measure of
39  patients with cutaneous, visceral, and post-kala azar visceral leishmaniasis indicated that a majori